The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIX.f

Anaphylaxis-Anaphylactoid reaction (can be fatal)

Publications

Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts AC

Safety-related regulatory actions for biologicals approved in the United States and the European Union.

JAMA 2008 Oct 22;300;1887-96 — 2008 Oct 22 — 1887-96

Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research 2001 Jun;7;1490-6 — 2001 Jun — 1490-6